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ABSTRACT
Objective Inhibition of food intake and glucose
homeostasis are both promoted when nutrients stimulate
enteroendocrine cells (EEC) to release gut hormones.
Several speciﬁc nutrient receptors may be located on EEC
that respond to dietary sugars, amino acids and fatty
acids. Bypass surgery for obesity and type II diabetes
works by shunting nutrients to the distal gut, where it
increases activation of nutrient receptors and mediator
release, but cellular mechanisms of activation are largely
unknown. We determined which nutrient receptors are
expressed in which gut regions and in which cells in
mouse and human, how they are associated with
different types of EEC, how they are activated leading to
hormone and 5-HT release.
Design and results mRNA expression of 17 nutrient
receptors and EEC mediators was assessed by
quantitative PCR and found throughout mouse and
human gut epithelium. Many species similarities
emerged, in particular the dense expression of several
receptors in the distal gut. Immunolabelling showed
speciﬁc colocalisation of receptors with EEC mediators
PYY and GLP-1 (L-cells) or 5-HT (enterochromafﬁn cells).
We exposed isolated proximal colonic mucosa to speciﬁc
nutrients, which recruited signalling pathways within
speciﬁc EEC extracellular receptor-regulated kinase (p-
ERK) and calmodulin kinase II ( pCAMKII), as shown by
subsequent immunolabelling, and activated release of
these mediators. Aromatic amino acids activated both
pathways in mouse, but in humans they induced only
pCAMKII, which was colocalised mainly with 5-HT
expression. Activation was pertussis toxin-sensitive. Fatty
acid (C12) potently activated p-ERK in human in all EEC
types and evoked potent release of all three mediators.
Conclusions Speciﬁc nutrient receptors associate with
distinct activation pathways within EEC. These may
provide discrete, complementary pharmacological targets
for intervention in obesity and type II diabetes.
INTRODUCTION
Nutrient sensing in the gut epithelium is fundamen-
tal to glucose homeostasis, energy intake, motor
and secretory function. Mechanisms of carbohy-
drate sensing are becoming better understood, but
those of protein, amino acid (AA) and fatty acid
sensing are less well described, especially in
humans. Improved knowledge of the sites and
mechanisms of nutrient sensing will ultimately
allow us to optimise the control of glycaemia and
gastroparesis in type II diabetes, hyperphagia
associated with obesity and hypophagia associated
with aging.
Nutrients are sensed by enteroendocrine cells
(EEC) as breakdown products of carbohydrate, fat
and protein digestion. This may occur via activity
of the sodium-coupled transporters involved in AA
and glucose absorption, which excite the cells and
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Key messages
What is already known on this subject?
▸ Luminal nutrients stimulate enteroendocrine
cells (EEC) to release mediators that potently
inhibit appetite and promote glucose
homeostasis.
▸ Several speciﬁc G-protein-coupled nutrient
receptors (GPCR) exist for dietary sugars, amino
acids and fatty acids, which may be expressed
on EEC.
▸ Activation of nutrient receptors and mediator
release from the distal gut is central to the
action of bypass surgery for obesity and type II
diabetes, but cellular mechanisms of activation
are largely unknown.
What are the new ﬁndings?
▸ Nutrient receptors for fatty acids and amino
acids are expressed throughout mouse and
human gut epithelium, notably in the large
intestine.
▸ There is speciﬁc colocalisation of receptors with
speciﬁc EEC mediators, for example,
calcium-sensing receptors and 5-HT.
▸ Luminal nutrient exposure activates mediator
release and recruits speciﬁc GPCR signalling
pathways within EEC cells: in humans,
tryptophan and phenylalanine activate only
pCAMKII in enterochromafﬁn cells, whereas
lauric acid activates p-ERK.
How might it impact on clinical practice in the
foreseeable future?
▸ It is already known that oral nutrient preloads
reduce subsequent food intake and that bypass
surgery reduces food intake by shunting
nutrient to the distal gut. By reﬁning nutrient
preloads and formulating them to target the
distal gut, we expect to develop a successful
weight loss and antidiabetic strategy prior to,
and possibly in place of, bypass surgery.
Neurogastroenterology
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lead to release of mediators such as glucagon-like peptide 1
(GLP-1) in the case of L-cells.1 2 Circulating GLP-1 then boosts
pancreatic insulin release. L-cells also release peptide YY (PYY),
which is important in suppressing appetite. There are several
other classes of EECs, one of the most important being the
enterochromafﬁn cell (EC), which releases mainly 5-
hydroxytryptamine (5-HT). The role of EC in nutrient sensing
is evident in the blockade of sensory3 nerve responses to intra-
luminal glucose by a 5-HT3 receptor antagonist,4 but their role
in glycaemic and appetite control is unclear. In addition to the
transporter-mediated release of gut mediators, there are speciﬁc
G-protein-coupled receptors (GPCR) for sugars (a dimer of
T1R2 and T1R3), and free fatty acids, including FFAR1, 2 and
3 (also known as GPR40, 43 and 41, respectively), GPR84 and
GPR120. In some cases, receptors have been found in the gut
and colocalised in EECs5 with hormones such as PYY and
GLP-1.1 6 7 Protein breakdown products may also act via a spe-
ciﬁc receptor, GPR93,8 and speciﬁc AAs act via calcium-sensing
receptors (CaSR), GPRC6A, T1R1 and the metabotropic glu-
tamate receptor mGluR4.9 However, very little is known about
the expression and colocalisation of these receptors in human
gut, in which regions they are found and how this compares
with data from other species. Since nutrient absorption is pri-
marily achieved in the small intestine, it is assumed that detec-
tion of nutrients and feedback control of energy intake is also
mediated there. However, the potent effects of gastric bypass
surgery on energy intake and glycaemic control indicate that
diverting nutrient to the distal small intestine and large intestine
can initiate major effects on energy intake. Moreover, products
of primary protein and fat digestion can be found in the normal
colon,3 and nutrients administered in the distal gut have potent
effects on upper gut function.10
Bypass surgery is the most effective current intervention in
obesity and type II diabetes. By shunting nutrient to distal
regions of the intestine, it causes copious postprandial release of
satiety and incretin hormones PYY and GLP-1 via chemosensory
mechanisms.11 There are large and rapid beneﬁts in terms of
weight loss and blood glucose homeostasis that coincide with
PYY and GLP-1 levels.12–14 Improved glycaemia precedes weight
loss, but the two are inextricably linked. Despite these advan-
tages, surgical treatments have several drawbacks, including
their application in only severe cases due to irreversibility, and
cost. Not surprisingly, there is growing interest among gastroen-
terologists and endocrinologists in developing non-surgical ther-
apies that lead to a reduction in energy intake, weight loss and
resolution of type II diabetes. Targeting the initiation of the
satiety signal arising from the GI tract is an attractive option. It
is also becoming apparent that protein digestion products have
potent effects on hormone release and glycaemic control, which
may be of therapeutic beneﬁt,15 although the mechanism of
these actions is currently unclear. Accordingly, we are pursuing
the opportunity to intervene directly with fatty acid, AA and
protein-sensing pathways of the distal gut to modify endocrine
responses.
We hypothesised that nutrient receptor expression is pre-
served in the distal gut and is able to elicit responses to spe-
ciﬁc luminal nutrients. We show how patterns of expression
of nutrient receptors along the gut are comparable in human
and mouse, how they may couple with release of gut hor-
mones from specialised cells in humans and which signalling
cascades are responsible. Gleaning this information we hope
will reveal a diverse range of targets for future antiobesity
treatments that will directly address the aetiology of the
condition.
METHODS
Animal studies were approved by the Animal Ethics Committees
of the University of Adelaide and Central Northern Adelaide
Health Service. All animal procedures in the UK were con-
ducted in compliance with the Home Ofﬁce guidelines. Human
studies were approved by the Human Research Ethics
Committees of the Royal Adelaide Hospital or Barts and The
London NHS Trust, and were performed with written informed
consent.
Mice
Experiments were performed using adult female C57BL/6 mice
maintained on standard laboratory chow and water in a con-
trolled environment (12 h light/dark cycle, 22±0.5°C, 40–60%
humidity) within a pathogen-free facility. Mice were killed by
CO2 asphyxiation. For expression analysis, the following were
collected: antrum, small intestine (proximal 2 cm was desig-
nated as duodenum, with the remainder divided equally into
proximal, mid and distal jejunum and ileum), caecum and large
intestine (proximal and distal). Mucosa from each segment was
collected by scraping, frozen in liquid N2 and stored (−80°C)
for later gene expression measurements. For immunohistochem-
istry, intact tissues were ﬁxed in 4% paraformaldehyde (2 h),
cryoprotected and mounted for sectioning. For Ussing chamber
experiments, the proximal colon was rapidly removed, opened
and pinned ﬂat for 30 min with the mucosa facing up before
being placed into the divided Ussing chamber.
Human tissue collection
Biopsies from histologically normal intestinal mucosa were col-
lected for gene expression studies from fasted subjects undergo-
ing surveillance enteroscopy or colonoscopy. Biopsies were
collected from the antrum, duodenum, proximal and mid-
jejunum (mean depth 167 cm) and, separately, from the right,
transverse and left colon, and rectum and were histologically
normal. All biopsies were stored in RNAlater at −20°C (Qiagen)
prior to gene expression measurements.
For immunohistochemistry, full-thickness samples of human
proximal colon were obtained from patients undergoing surgery
for GI cancer. Following surgical resection, non-pathological
tissue was ﬁxed in Zamboni’s ﬁxative (4°C overnight). Tissues
were cryoprotected in 30% sucrose/phosphate buffered saline
then mounted in optimum cutting temperature medium.
For Ussing chamber studies, ascending colonic tissue was
obtained from patients undergoing right hemicolectomy.
Non-pathological full-thickness samples were isolated and
placed in cold carbogenated Krebs solution before excision of
muscular and serosal layers from the mucosa in a silicone-ﬁlled
Petri dish. The remaining mucosa was pinned ﬂat facing up
before being placed into the Ussing chamber.
Where hormone/peptide release was measured, four ascend-
ing colon biopsies/patient were collected from 15 patients.
Tissue was immediately placed in cold carbogenated Krebs solu-
tion before being transferred to a 96-well plate containing nutri-
ent and control solutions.
Gene expression studies
Quantitative real-time reverse transcriptase PCR (RT-PCR) was
used to assess relative expression of nutrient GPCRs (see online
supplementary table S1) in mice and humans. Regional expres-
sion of the GI appetite hormones CCK, PYY and GCG was also
determined in mouse.
Neurogastroenterology
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RNA was extracted from tissues using an RNeasy Mini kit
(Qiagen). RNA quantity and quality was assessed using a
NanoDrop. RT-PCR was performed as previously described.16
Primers (see online supplementary table S1) were designed and
purchased from Geneworks (Adelaide, Australia); speciﬁcity was
conﬁrmed via product size by gel electrophoresis. Target gene
expression was determined relative to endogenous controls
using the comparative cycle threshold method normalised to
glyceraldehyde 3-phosphatase dehydrogenase (GAPDH) or
β-actin expression.17
Ussing chamber experiments
Mouse and human colonic mucosa were divided into three
1×1 cm segments, and each segment was mounted in an Ussing
ﬂux chamber. The luminal surface was exposed to 10 mL nutri-
ent solution, and the basolateral surface was exposed to 10 mL
Krebs solution for 20 min. All solutions were carbogenated at
35–37°C. Colonic mucosa was then ﬁxed in 4% paraformalde-
hyde overnight.
Release assays
Collected biopsies (N=3–6) were incubated with 250 μL of car-
bogenated solutions of buffer (control) or nutrient in a 96-well
plate for 15 min (5-HT assay) or 2 h (GLP-1 and PYY assay) at
37°C. A customised tissue culture medium with 4.4 mM
L-glutamine and 6 mM glucose was used in order to ensure cells
were healthy but not stimulated with nutrients. DPPIV inhibitor,
PK 44 phosphatase (50 nM), was added to buffer in GLP-1
experiments, while monoamine oxidase inhibitor moclobemide
(10 nM) and selective serotonin reuptake inhibitor ﬂuoxetine
(10 mM) were used in the 5-HT to prevent breakdown and
reuptake. Following incubation, supernatants were collected and
stored at −20°C. GLP-1 and PYY protein levels were quantitated
using a human multiplex kit according to manufacturer’s
instructions (Milliplex MAP Multiplex assay, Merck Millipore),
with ghrelin and gastric inhibitory polypeptide (GIP) included
as comparators. 5-HT was measured using an ELISA (BA
E-5900, Labor Diagnostika Nord). Addition of nutrients to
control supernatants after the study did not affect readings, so
their presence did not interfere with assays.
Nutrient solutions
The luminal side of mouse colonic mucosa was exposed to
1 and 10 mmol/L phenylalanine (Phe) and tryptophan (Trp)
while human ascending colon was exposed to 25 and 50 mmol/
L Phe/Trp (selective activators of the CaSR). Lauric acid (LA,
12.5 and 25 mmol/L) was used as an agonist of GPR84 in separ-
ate experiments. We further investigated the intracellular
pathway involved in activation and its relationship with medi-
ator release by interference with G-protein coupling using per-
tussis toxin (PT, 200 ng/mL). Nutrients made up in Krebs
solutions were either normal or high calcium (for Phe/Trp
experiments). All solutions contained 124.05 mM NaCl
(Sigma), 4.78 mM KCl (AnalR), 1.33 mM NaH2PO4 (Sigma),
2.44 mM MgSO4 (Sigma), 5.50 mM D-glucose (Sigma) and
25.00 mM NaHCO3 (Sigma) and carbogenated with 95% O2
and 5% CO2. Normal and high calcium solutions also contained
2.50 and 5.05 mM CaCl2, respectively.
Immunohistochemistry
Immunolabelling for GPRC6A, T1R2, GPR93 and FFAR3 was
assessed in mouse proximal jejunum and colon, with the latter
three targets colocalised with CCK in jejunum and PYY/GLP-1
in colon (see online supplementary table S2). Colocalisation of
CaSR and GLP-1/PYY/5-HT was also determined in human
colon while pERK and pCamKII was performed in human
and mouse Ussing chamber experiments (see online supplemen-
tary table S2). Brieﬂy, 10 μm sections were washed with a
blocking buffer, the primary antibody was applied (19 h, 4°C),
tissues were then washed and incubated (60 min, room tempera-
ture) with species-speciﬁc Alexa Fluor conjugated secondary
antibodies (1:200, Invitrogen). Sections were imaged as
previously described.16 Immunopositive cells for each target
were manually counted in each section and averaged over ﬁve
ﬁelds of view.
Statistical analysis
Data are expressed as mean±SEM. Statistical analysis was per-
formed using one-way analysis of variance and Tukey’s post hoc
test (GraphPad Prism, V.5.02, GraphPad Software, Inc), with
p<0.05 considered statistically signiﬁcant. For the release assays,
unpaired, one-tailed t tests were used and statistical signiﬁcance
was tested using Mann–Whitney post hoc test with p<0.05
deﬁned as signiﬁcant.
RESULTS
Nutrient receptor distribution
In order to answer the question of which receptors are present
to sense nutrients in the GI tract, we ﬁrst investigated the rela-
tive distribution of the major candidates throughout the mouse
and human gut using quantitative measurement of their tran-
scripts. Nutrient GPCRs were expressed throughout the mouse
GI tract from stomach to colon, with the exception of the sweet
taste receptor T1R2 that was detected only in the small intestine
(ﬁgure 1). The bile acid sensor TGR5 did not reveal any
regional speciﬁcity. The protein hydrolysate receptor GPR93
showed highest expression levels in the mid-intestine, peaking in
the distal jejunum. The AA receptors CaSR, mGluR4 and T1R1
were more highly expressed distally, with peak expression
evident in the caecum (CaSR) and proximal colon (mGluR4,
T1R1). Expression of the T1R1 coreceptor T1R3 was highest in
the ileum. The short chain fatty acid (SCFA) receptor FFAR2
was highly expressed in the proximal colon, while FFAR3
peaked in the distal jejunum. Both the medium CFA (MCFA)
receptor GPR84 and the dual MCFA and long CFA (LCFA)
receptor FFAR1 were highest in the ileum, while GPR120 levels
peaked in the proximal colon. The oleoylethanolamide receptor
GPR119 showed highest expression in the distal GI tract. As
expected, cholecystokinin (CCK) transcript levels were highest
in the small intestine, whereas glucagon (GCG) and PYY expres-
sion peaked in the proximal and distal colon, respectively (see
online supplementary ﬁgure S1).
Since the diet and food intake behaviour of humans and mice
differ considerably, it was important to determine whether pat-
terns of expression were conserved between these species. This
was generally the case since all nutrient GPCRs were expressed
in biopsies collected over the length of the human GI tract, with
the exception of T1R2, which was only detected within the
small intestine of both species (ﬁgure 2). GPR93 was the most
highly expressed receptor in the small intestinal mucosa in mice
and humans, while the LCFA receptor GRP120 was highest in
the large intestine. GPR93 and the SCFA receptor FFAR2 were
also highly expressed in the large intestine in both species.
GPCRs within EECs
Immunolabelling for T1R2, GPR93 and FFAR3 was assessed in
mice in combination with CCK labelling in the mouse jejunum,
and with GLP-1 and PYY in the colon, since mRNA for these
Neurogastroenterology
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mediators was predominant in these locations (see online
supplementary ﬁgure S1). T1R2 did not colocalise with
CCK, whereas 32% of FFAR3-positive cells were CCK-
immunoreactive (IR) (see online supplementary ﬁgure S2).
Colonic L-cells were IR for GLP-1 and PYY, and were frequently
associated with GPR93 and FFAR3 labelling (ﬁgure 1E, F).
Similar colocalisation of GLP-1 and PYY was found in the
ascending colon in humans with 69% overlap of cells labelled
with each individually. As our interest was particularly in the
role of the distal gut in nutrient sensing, colocalisation of CaSR
with the major EECs mediators PYY, GLP-1 and 5-HT was
examined using double-staining immunolabelling. The data in
ﬁgure 2E indicate that although a signiﬁcant population of
L-cells (GLP-1 and/or PYY-IR) expressed CaSR, the majority of
CaSR expressing cells did not colocalise. Instead, they were fre-
quently associated with 5-HT-IR (91%), suggesting that CaSR
signalling may act to preferentially release 5-HT in the human
ascending colon. The greatest number of CaSR-IR cells in
humans was found within the antrum (see online supplementary
ﬁgure S3), consistent with its established role in AA-evoked
gastrin release,18 followed by the ileum and colon. The predom-
inance of 5-HT colocalisation with CaSR in colon was not seen
in mouse (see online supplementary ﬁgure S4), suggesting
species differences.
Figure 1 Regional expression in mouse GI tract of the G-protein coupled receptors (GPCR) for carbohydrate-sweet T1R2 (A), bile acids, TGR5 (B),
amino acids, GPR93, T1R3, CaSR, mGluR4 and T1R1 (C), fatty acids GRP120, FFAR3, FFAR1, FFAR2, GPR84 and GPR119 (D), relative to GAPDH
(n=7 for all expression studies). (E and F) Immunolabelling in mouse proximal colon for GPR93, FFAR3, GLP-1 and PYY in mouse proximal colon.
Charts represent the proportion of individual GPCRs colocalised with cells expressing GLP-1 or PYY (yellow), those with GPCR alone (green) and
those with hormone alone (red).
Neurogastroenterology
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Downstream pathways activated by CaSR
As we found expression of AA sensing receptor mRNA in
mouse and human distal GI tract, and expression of CaSR
protein in the human colon, we explored the functional role of
this receptor in activation of appetite regulation pathways. The
cell activation markers phospho-extracellular signal-regulated
kinase (pERK) and pCaMKII were used as markers of general
cellular activation. In mouse proximal colon, in response to
stimulation with the CaSR agonists phenylalanine and trypto-
phan (Phe/Trp), we observed increased pERK (ﬁgure 3A) and
pCaMKII (ﬁgure 3B) expression compared with buffer control.
These markers revealed different patterns of activation of cell
groups (pERK; ﬁgure 3C (i)) or individual cells (pCAMKII;
ﬁgure 3C (ii)). This pattern of pERK activation may suggest
entrainment of cells neighbouring some types of EECs, but not
others. In order to conﬁrm that these effects were receptor-
mediated, we repeated the experiments with the CaSR selective
agonist cinacalcet (1 mM),19 which showed similar induction of acti-
vation markers to Phe/Trp (see online supplementary ﬁgure S5).
The effects of CaSR stimulation were also studied in the
human proximal colon. pCaMKII induction was concentration-
dependent in response to Phe/Trp (ﬁgure 4A), whereas in con-
trast to the mouse, we never observed pERK induction above
baseline. Since CaSR was present mainly in 5-HT-containing
cells rather than L-cells (ﬁgure 2E), we investigated the presence
of 5-HT or GLP-1 in the activated cells. This experiment con-
ﬁrmed the association of the CaSR with 5-HT-containing cells
(ﬁgure 4B). Following luminal exposure to 25 mmol/L Phe/Trp,
four times more 5-HT-IR cells exhibited colocalised pCamKII-IR
(42±11%) than under control conditions (10±5%, p<0.01,
Figure 2 Regional expression in human GI tract of the G-protein coupled receptors (GPCR) for carbohydrate-sweet T1R2 (A), bile acids, TGR5 (B),
amino acids, GPR93, T1R3, CaSR, mGluR4, T1R1 (C), fatty acids GRP120, FFAR3, FFAR1, FFAR2, GPR84 and GPR119 (D) relative to β-actin (n=6 for
all expression studies). (E) Immunolabelling in human proximal colon for CaSR, GLP-1, PYY and 5-HT. Chart represents the proportion of individual
cells colocalised with PYY, GLP-1 or 5-HT with and without CaSR.
Neurogastroenterology
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n=10). GLP-1 cells also showed CamKII activation, although to a
lesser extent (29±5% p<0.01).
As pERK was induced in mouse but not human tissue, this
raised the possibility that the pERK pathway was species spe-
ciﬁc. In order to determine whether pERK was in fact inducible
by nutrients in human tissue, we investigated the effect of LA,
which is known to be a potent releaser of hormones other than
5-HT.20 There was indeed a concentration-dependent increase
in the number of pERK-IR cells in the human proximal colon
after exposure to LA (ﬁgure 4C), which we showed to occur in
both 5-HT-containing and L-cells (see online supplementary
ﬁgure S6).
CaSR is coupled via Gαq and Gαi/o G-proteins, so we wanted
to conﬁrm such a mechanism was involved in the response of
human EEC to Phe/Trp. Therefore, PTwas used to block activa-
tion of Gi/o and thus downstream activation. Pretreatment with
PT resulted in a signiﬁcant decrease in the number of
pCAMKII-activated cells/crypt (ﬁgure 5), conﬁrming G-protein
involvement. Therefore, with regards to CaSR coupling in
human, it appears to activate via G-proteins, which are in turn
coupled with either pCAMKII in 5-HT-containing ECs, or a dif-
ferent mechanism in L-cells, but not to pERK.
Mediator release
As we found activation of EEC in mouse and human distal GI
tract, and expression of CaSR and GPR84 in the human colon,
we explored the functional consequence of receptor activation
by measuring release of the three mediators that we examined
immunohistochemically. LA (which activates GPR84 most
potently) evoked signiﬁcantly more release of all three mediators
compared with control, whereas Phe/Trp (which activate CaSR
most potently) evoked increased release only of GLP-1, with
trends towards increases of PYY and 5-HT (ﬁgure 6). Neither of
these stimuli evoked release of GIP or ghrelin (data not shown).
DISCUSSION
In this study, we have gained insight into which receptors
mediate satiating actions of nutrients in the GI tract.
Throughout the mouse and the human GI tract, AA and FA
receptors were expressed from stomach to colon, with a high
level of species similarity and conservation of expression in the
distal gut. We found speciﬁc colocalisation of receptors with
speciﬁc EEC mediators, for example, calcium-sensing receptor
and 5-HT, suggesting a ﬁne-tuning of EEC for particular stimuli.
This was evident in functional studies: in human colon, AAs
preferentially activate one intracellular signalling pathway
(pCamKII) in 5-HT containing cells, whereas fatty acid activates
another (p-ERK) in GLP-1- and/or PYY-containing cells.
As previously shown, the EEC mediator cholecystokinin
(CCK) was found mainly in the small intestine, whereas gluca-
gon (GCG) and PYY gene expression peaked in the colon.
Carbohydrate in the intestinal lumen is not associated with
CCK release, whereas protein and fat generally is.
Correspondingly we found T1R2 did not colocalise with CCK,
whereas 32% of FFAR3-positive cells were CCK-IR. Colonic
L-cells were IR for GLP-1 and PYY, and were frequently asso-
ciated with GPR93 and FFAR3 labelling, again suggesting a link
with protein and fat sensing. Although a signiﬁcant population
of L-cells (GLP-1 and/or PYY-IR) expressed CaSR, the majority
of CaSR-expressing cells did not colocalise. Instead, they were
almost exclusively associated with 5-HT-IR. These observations
are consistent with overlapping lineages of EECs, with ECs
having a largely non-overlapping phenotype to others.21
To determine the functional role of nutrient receptors in acti-
vation of appetite regulation pathways, we looked for markers
Figure 3 Effects of phenylalanine and tryptophan (1 and 10 mmol/L) on enzyme phosphorylation in sheets of mouse proximal colonic mucosa.
There was a signiﬁcant increase in the number of pERK-IR (A) and pCamKII-IR (B) cells following stimulation at both concentrations (*p<0.05)
compared with control. pERK-IR cells were commonly observed in groups towards the apical aspect of mucosal villi. Within pERK-positive cell
groups, one or two cells often stained more positively than surrounding IR cells (C (i), arrows). Comparatively fewer pERK-positive cells appeared in
crypts. The opposite was true for pCamKII-IR cells (C (ii) and schematic in (iii)). Insets show 40× magniﬁcation of activated cells. Scale bar 15 μm.
Neurogastroenterology
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of cell activation. Extracellular signal-regulated kinase (ERK)
becomes phosphorylated as a result of a cascade of activation by
GPCRs coupled via Gq and Ras-Raf proteins in many systems
and interacts with pathways of secretion, gene expression and
cell metabolism.22 Calmodulin kinase (CaMKII) is activated by
increases in intracellular calcium normally associated with
release from intracellular stores following Gq activation of
phospholipase C and stimulation of ryanodine receptors on
endoplasmic reticulum.23 This pathway is activated alongside
the intracellular calcium-dependent docking of secretory vesi-
cles. Therefore, these two intracellular pathways may have con-
vergent and divergent effects, and share the feature of
Gq-protein activation.23 The majority of nutrient receptors are
coupled via this G-protein, so the markers we chose to investi-
gate are likely to reveal alternative downstream cascades.
pCaMKII has been previously shown to be a suitable marker for
activated EEC in stimulated intact mucosa. pERK is well estab-
lished as a component of synaptic neural activation.24
In mouse proximal colon, in response to stimulation with the
CaSR agonists phenylalanine and tryptophan, both markers
were induced but revealed different patterns of activation.
pERK was induced in cell groups in several cases, whereas
pCAMKII was activated only in individual cells. The pattern of
pERK activation suggests entrainment of cells neighbouring
Figure 4 (A) Human ascending colonic mucosa was stimulated with 25 and 50 mmol/L Phe/Trp or high calcium Krebs as control. There was a
signiﬁcant increase in the number of pCamKII-IR cells following stimulation at both concentrations (*p<0.05) compared with control. pERK-IR was
not induced (not shown). Scale bar 15 μm. (B) In human colon, Phe/trp at 25 mmol/L resulted in speciﬁc activation of 5-HT-IR pCaMKII cells, while
GLP-1 cells were not found to colocalise with pCamKII. 5-HT-IR and GLP-IR were found predominantly in the basolateral membrane (insets),
suggesting that the peptide was located in vesicles in anticipation of release following CaSR stimulation. Scale bar 15 μm. (C) Effect of lauric acid
(12.5 and 25 mmol/L) on pERK-IR in sheets of human proximal colonic mucosa. There was a concentration-dependent increase in the number of IR
cells with increasing concentrations (*p<0.05) compared with control. Scale bar 15 μm.
Figure 5 Phe/trp stimulation of
human ascending colon mucosa
pretreated with pertussis toxin (+PT)
resulted in a signiﬁcant decrease in the
number of pCamKII-IR cells/crypt
(arrows) compared with untreated
controls (−PT, *p<0.05). Scale bar
20 mm.
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some types of EEC, but not others. We speculate that this may
be a mechanism of paracrine control of absorptive, immune or
proliferative function of colonocytes. The effects of CaSR stimu-
lation were different in the human proximal colon. pCaMKII
was induced concentration-dependently in response to Phe/Trp,
whereas in contrast to the mouse, we did not observe pERK
induction. It was therefore important to determine whether a
GPCR mechanism was still involved. This was conﬁrmed using
PT to block activation of G-proteins. These data raised the pos-
sibility that pERK was a marker of nutrient receptor activation
only in the mouse, so we investigated responses to another
nutrient for which receptors are present in the human colon.
Therefore, we incubated human tissue with LA (12.5 and
25 mM), which is an agonist of GPR84 and evokes PYY and
GLP-1 release.20 This evoked powerful pERK responses in a
large number of EECs, indicating that there are different path-
ways involved in aromatic AA and MCFA sensing in different
cell types. Correspondingly, LA evoked potent release of all
three EEC mediators.
Since CaSR was present mainly in 5-HT-containing cells
rather than L-cells (ﬁgure 2E), we investigated the presence of
5-HT or GLP-1 in the activated cells. This experiment con-
ﬁrmed the association of the Phe/Trp-sensing receptor CaSR
mainly with 5-HT-containing cells (ﬁgure 3D). Therefore, with
regards to CaSR coupling, it appears to activate human EE cells
via G-proteins, which are in turn coupled with pCAMKII in 5--
HT-containing ECs, and may involve in addition a different
mechanism in L-cells, but one that is independent from pERK.
Conclusions
We conclude that the distal gut of humans and mice is exten-
sively equipped with sensors for products of fat and protein
digestion, and that these associate with speciﬁc signalling path-
ways, two of which have been shown here. These are in turn
associated with the release of speciﬁc mediators. We have uncov-
ered a role for 5-HT in the response to luminal aromatic AAs,
which may contribute to metabolic and behavioural responses
to exposure of the distal gut to a meal. It is already known that
oral nutrient preloads reduce subsequent food intake15 and that
bypass surgery reduces food intake by shunting nutrient to the
distal gut. By reﬁning nutrient preloads and formulating them
to target the distal gut, we expect to develop a successful weight
loss and antidiabetic strategy prior to and possibly in place of
bypass surgery.
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